ibidi Receives the Prestigious "FINALIST" Industry Award 2016 for the µ-Slide Membrane ibiPore Flow

Munich, Germany, (PresseBox) - ibidi GmbH, a leading supplier of products used for analyzing living cells, received a distinguished „FINALIST” INDUSTRIEPREIS 2016, in the Biotechnology category, for their unique µ-Slide Membrane ibiPore Flow—a product designed for migration and transport studies on cells.

This is the second time since 2012 that ibidi has been awarded this honor by the publishing company, “Huber Verlag für Neue Medien GmbH”. For the past eleven years, under the patronage of the “Verein Deutscher Ingenieure (Association of German Engineers)”, prizes have been presented to companies that offer exceptional commercial, social, technological, and ecological benefits. This year, ibidi finished as one of the top 3 companies in the Biotechnology category. In total, more than 500 applicants participated in the contest.

The new µ-Slide Membrane ibiPore Flow enables researchers to culture single or multiple cell types on a porous glass membrane, and then analyze the cells using high-resolution microscopy—something that is not currently possible when using typical polymer cell culture inserts.

This special microscopy chamber contains a cross-channel structure with a thin, porous, optical glass membrane located in between. Cells can be cultured on both sides of the glass membrane and then visualized using phase contrast or fluorescence microscopy. The special construction of the slide allows full fluidic access to the apical and basal sides of adherent cells for cell studies under static or flow conditions.

Typical applications include, the co-culture of smooth muscle cells with endothelial cells under perfusion, the trans-migration of leukocytes with dynamic shear stress, and invasion assays using cancer cells.

„For the first time, when using the µ-Slide Membrane ibiPore Flow, it is possible to investigate how tumor cells manage to reach the bloodstream”, explains Dr. Roman Zantl, President of ibidi GmbH. “The detailed information that can finally be obtained could help prevent the generation of metastases. We are very pleased that ibidi’s commitment to our customers in medicine and biotechnology has been acknowledged with the „FINALIST” INDUSTRIEPREIS 2016.”

ibidi’s technology development is continually supported by the BMBF (Bundesministerium für Bildung und Forschung), amongst others as part of the research project “Optical Technologies (Biophotonics)“ and the “KMU-innovative” program. “This, and additional product developments, would not have been possible without the intensive support of our research activities,” states Dr. Valentin Kahl, CEO at ibidi GmbH.

ibidi GmbH

ibidi® GmbH, located in Martinsried near Munich, Germany, is a leading supplier of functional, cell-based assays, and products for cell microscopy. ibidi's range of products offers solutions for classic cell culturing, and also complex assays (e.g., angiogenesis, chemotaxis, and wound healing). Their products help facilitate an understanding of the development of various diseases and related therapies. ibidi's customers are working in scientific institutions, industrial pharmacology, and biotechnology. Technology development at ibidi is supported by the BMBF (Bundesministerium für Bildung und Forschung). The products are sold to customers worldwide.


Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

Was erwartet die datengetriebene Wirtschaft 2018?

Künst­li­che In­tel­li­genz (KI) war ver­gan­ge­nes Jahr ei­nes der Trend­the­men. Und auch in den Ex­per­ten­prog­no­sen für 2018 ist sie ein fes­ter Be­stand­teil. Die Fra­ge ist al­so we­ni­ger, ob, son­dern wie KI und da­mit ver­bun­de­ne Tech­no­lo­gi­en wie Ma­chi­ne Lear­ning in den nächs­ten Mo­na­ten die Un­ter­neh­mens­welt ve­r­än­dern wer­den.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.